Since the efficacy of MEK or KRASG12C inhibitors monotherapy in RAS mutant cancer is limited due to feedback reactivation of RAS downstream pathways, identification of potential combination strategies through synthetic lethal screens could be the key to achieve maximum and durable suppression of RAS signaling in tumors and improve patient response. Here, MAP2K7 is linked to cancer.